Company Update (NASDAQ:GILD): Texas Medicaid holds off on proposed limits for Gilead hepatitis drug

[Reuters] – Texas is reconsidering whether to impose strict limits on Gilead Sciences’ $84,000 hepatitis C treatment for patients on the state’s Medicaid health plan for the poor, at the urging of outside . . . → Read More: Company Update (NASDAQ:GILD): Texas Medicaid holds off on proposed limits for Gilead hepatitis drug Similar Articles: Company Update – Gilead Sciences Inc. (NASDAQ:GILD) – Mounting optimism for hepatitis C drug boosts Gilead to lead S&P 500 Gilead Sciences Inc. (NASDAQ:GILD) – Gilead to seek okay for combo hepatitis C pill in Q1 Stock Update: Johnson & Johnson (NYSE:JNJ) – J&J’s new hepatitis C drug gets positive FDA review